- Home
- APLT vs DPRO Comparison
APLT vs DPRO Comparison
Compare APLT & DPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- DPRO
- Stock Information
- Founded
- APLT 2016
- DPRO 1998
- Country
- APLT United States
- DPRO Canada
- Employees
- APLT N/A
- DPRO N/A
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- DPRO Aerospace
- Sector
- APLT Health Care
- DPRO Industrials
- Exchange
- APLT Nasdaq
- DPRO Nasdaq
- Market Cap
- APLT 178.6M
- DPRO 175.1M
- IPO Year
- APLT 2019
- DPRO N/A
- Fundamental
- Price
- APLT $1.28
- DPRO $8.54
- Analyst Decision
- APLT Buy
- DPRO Strong Buy
- Analyst Count
- APLT 5
- DPRO 1
- Target Price
- APLT $4.13
- DPRO $14.00
- AVG Volume (30 Days)
- APLT 5.5M
- DPRO 6.6M
- Earning Date
- APLT 11-10-2025
- DPRO 11-13-2025
- Dividend Yield
- APLT N/A
- DPRO N/A
- EPS Growth
- APLT N/A
- DPRO N/A
- EPS
- APLT N/A
- DPRO N/A
- Revenue
- APLT $121,000.00
- DPRO $5,250,872.00
- Revenue This Year
- APLT N/A
- DPRO $41.59
- Revenue Next Year
- APLT $5,935.35
- DPRO $137.37
- P/E Ratio
- APLT N/A
- DPRO N/A
- Revenue Growth
- APLT N/A
- DPRO 17.08
- 52 Week Low
- APLT $0.30
- DPRO $1.63
- 52 Week High
- APLT $10.62
- DPRO $14.40
- Technical
- Relative Strength Index (RSI)
- APLT 60.36
- DPRO 48.53
- Support Level
- APLT $1.16
- DPRO $8.57
- Resistance Level
- APLT $1.50
- DPRO $10.19
- Average True Range (ATR)
- APLT 0.14
- DPRO 1.36
- MACD
- APLT -0.02
- DPRO -0.41
- Stochastic Oscillator
- APLT 61.64
- DPRO 16.98
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About DPRO Draganfly Inc.
Draganfly Inc is a Canada based company. It is engaged in the provision of engineering services and the manufacture of commercial unmanned vehicle systems and software. The company operates in Canada, the United States, and Internationally. The three segments are Drones, Vital (Vital Intelligence), and Corporate. The Drones segment derives its revenue from products and services related to the sale of unmanned aerial vehicles (UAV). The Vital segment derives its revenue from the sale of products that measure vitals to help detect symptoms from large groups of people from a distance. The Corporate segment includes all costs not directly associated with the Drone and Vital segments. It generates majority of its revenue from Drones segment.